MCL1 and Miyoshi myopathy: Preclinical studies have shown that both the dexamethasone and the proteasome inhibitors (bortezomib and carfilzomib) can increase BCL­2 dependency in MM cells by shifting MCL­1 to BCL­2 and by decreasing MCL­1 activity through the upregulation of Noxa (PMAIP1) [32–36].